drugset / Trial / NCT04049825
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.
Timeline
- Start
- 2019-11-22
- Primary completion
- 2025-03-25
- Completion
- 2026-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPB-111077 | Small molecule | 200 mg | — |
| Subject | OPB-111077 | Small molecule | 400 mg | — |
| Subject | OPB-111077 | Small molecule | 600 mg | — |
| Background | Bendamustine | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |